Suzhou Ribo Life Science and Ribocure Pharmaceuticals announced the submission of a Phase 2 clinical trial application to the EMA for siRNA-based therapy aimed at coronary artery disease, marking a significant advancement in thromboembolic treatment.

Suzhou Ribo Life Science and Madrigal Pharmaceuticals celebrate a significant milestone in the development of novel siRNA therapies for MASH, a liver disease.

Suzhou Ribo Life Science announces an important phase 2 clinical trial submission for siRNA therapy targeting coronary artery disease, enhancing antithrombotic treatment options.

Argo Biopharma has initiated the Phase I clinical trial of BW-41012, an innovative siRNA therapy targeting Factor XI for thromboembolic diseases, marking a significant advancement in their RNAi pipeline.

Suzhou Ribo Life Science unveiled promising Phase 2a trial results for Vortosiran, a revolutionary siRNA therapy showing significant FXI inhibition in coronary artery disease patients.

Argo Biopharma has commenced Phase II clinical trials for BW-40202, targeting serious conditions like PNH and IgAN. This innovative siRNA therapy aims to improve patient outcomes.

Ribo Life Science Co., Ltd. has made a triumphant entry onto the Hong Kong Stock Exchange Main Board, signaling a significant advancement in siRNA therapeutics. This momentous step boosts the biopharmaceutical sector.

Mabwell and Aditum Bio have joined forces to create Kalexo Bio, aiming to advance siRNA therapy for cardiovascular disorders through innovative research.

Rona Therapeutics has announced FDA IND clearance to advance RN0361, a targeted siRNA therapy for managing hypertriglyceridemia in patients after promising Phase 1 results.